Clinical trial · Interventional
Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old
A Multicenter，Open-label，Randomized Study on the Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old
NCT02432911CI-TRIAL-00024182unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study focus on the comparison of CAG regimen to the low dose cytarabine therapy in elderly AML patients who are unfit or unwilling to receive intensive chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF) | Drug | — | UNRESOLVED |
| low dose cytarabine | Drug | Cytarabine | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- CAG regimen
- description
- Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
- interventionNames
- Drug: CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)
- type
- ACTIVE_COMPARATOR
- label
- Low dose cytarabine
- description
- cytarabine 20mg bid for 10 days.
- interventionNames
- Drug: low dose cytarabine
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Acute myeloid leukemia except APL * ECOG PS：0-3 * Unfit or unwilling to receive intensive therapy Exclusion Criteria: * The one who has already received induction therapy no matter what the outcome is. * Active cancer patients who are needed to receive treatment; * Serious uncontrolled infectious diseases(eg.tuberculosis or invasive pulmonary aspergillosis）； * Active heart disease
References
Publications (0)
Data not yet available
No reference posted for this study.